Biofile Acquires Biofons' ELISA Products

By Labmedica staff writers
Posted on 29 Dec 2004

All rights to the enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody (IFA) products of Biofons (Turku, Finland) have been acquired by Biofile Ltd. (also in Turku). No financial details were disclosed.

All key Biofons personnel from manufacturing and customer service related to the ELISA business have also been transferred from Biofons to Biofile. Biofile now owns all rights to the Biofons brand. Biofile develops, manufactures, and markets innovative diagnostic tests for autoimmune and infectious diseases for private and public clinical laboratories worldwide.

According to Biofile, the new product line will strengthen the company's existing product line. It includes the Biofons celiac disease panel and inflammatory bowel disease panel. The celiac disease panel includes five different tests: anti-gliadin IgA and IgG, anti-transglutaminase IgA and IgG, and endomysium IgA (hUC) IFA test.

Related Links:
Biofile
Biofons